How a New PBM Cuts Employer Drug Costs: The 2026 Playbook
Every employer I talk to wants to know where the “easy” savings are in their health plan. They expect me to say network discounts, or wellness, or a plan design change that shifts a little more cost to employees.
It’s none of those. It’s pharmacy. And the reason it’s the easiest place to find money is uncomfortable: most employers have never actually read the contract that governs it.
Pharmacy is roughly a quarter of what employers spend on healthcare, the National Business Group on Health put it at about 25% of total healthcare spend, and it is a category where the middleman’s business model is designed to be difficult to see. That’s not an accident. That’s the product.
The number that should bother you
Start with scale. CMS reported U.S. retail prescription drug expenditure at roughly $378 billion in 2021. HHS put total system-wide spending, before rebates, at $603 billion, with $421 billion of that in retail drugs.
Now ask the question almost nobody asks: of the rebate dollars generated by your employees’ prescriptions, how much actually landed back on your plan’s bottom line?
If you can’t answer that from your own contract in under five minutes, you have your answer. It didn’t.
How PBM money actually moves (the part nobody explains)
A pharmacy benefit manager sits between your plan, the pharmacy, and the drug manufacturer. It makes money in at least four places:
- Spread pricing. The PBM bills your plan one price for a drug and reimburses the pharmacy a lower one. The difference, the spread, is theirs. It never appears as a fee, because it isn’t one. It’s baked into the claim.
- Rebates. Manufacturers pay for formulary placement. Your contract may promise a percentage pass-through of “rebates,” while the definition of “rebate” in that same contract quietly excludes administrative fees, data fees, and other manufacturer payments that walk and talk exactly like rebates.
- Formulary steering. The drug with the biggest rebate is not always the cheapest net drug. A high-list, high-rebate brand can beat a low-cost generic on the PBM’s P&L while losing on yours.
- Owned pharmacies. When the PBM also owns the mail-order and specialty pharmacy filling your claims, “negotiating a discount” means negotiating with itself.
Every one of those is legal. Every one of them is disclosed somewhere. And every one of them is written in language that survives an HR review precisely because it was drafted to.
Why the rebate obsession is the wrong fight
The industry has trained employers to chase rebate guarantees. Bigger rebate = better deal, the logic goes. It’s the number brokers put on the spreadsheet because it’s the number that’s easy to compare.
It’s also the number most likely to mislead you.
A rebate is a percentage of an inflated list price. Chasing rebates rewards the plan for using expensive drugs. I have seen renewal proposals where the “improved” rebate guarantee was funded entirely by moving members onto higher-list-price brands, the employer got a bigger rebate check and a worse net cost. That is the whole trick.
The number that matters is net cost per member per month, after every fee, spread, and rebate.
Why the market looks the way it does
Three PBMs control roughly three-quarters of the market, and all three are Fortune 50 companies attached to insurance carriers. That structure explains a lot of behavior that otherwise looks irrational.
Your plan’s long-term cost trend is not on their scorecard. Quarterly earnings are. Those two goals overlap sometimes and diverge exactly when your claims get expensive.
This is the point I’d make to any employer waiting on Washington to fix it: pharmacy is not primarily an insurance problem. It’s a supply chain problem. Congress can force disclosure. It cannot make you read the disclosure, and it cannot renegotiate your contract for you.
What an independent PBM actually changes
“Independent” means the PBM isn’t owned by an insurance carrier and doesn’t make money on spread. It gets paid an administrative fee, and that’s it. Its economics no longer improve when your drug spend goes up.
What that buys you in practice:
- No spread pricing. You pay what the pharmacy is paid, plus a disclosed fee. One price, visible.
- 100% rebate pass-through — with a contract definition of “rebate” broad enough to mean something.
- Your claims data, in your hands. Not a quarterly PDF summary. The actual file, in a format you can audit.
- Clinical and formulary management aimed at net cost, not rebate yield, including real utilization review on specialty.
- Account management that answers the phone, which sounds trivial until you’re mid-year with a $40,000-a-month specialty claim and no one returning your call.
That last category is where the real money is. Specialty drug spending reached about $301 billion in 2021, up 43% since 2016, and represented roughly half of total drug spending. Meanwhile the top 10% of drugs by price account for under 1% of prescriptions but 15% of retail spending and 20–25% of non-retail spending.
Read that again: a handful of claims drive the outcome. Which is why employers who spend heavily on broad wellness initiatives while never touching their pharmacy contract are optimizing the wrong end of the plan.
What this looks like in the real world: True Fitness
True Fitness is a 113-employee St. Louis manufacturer that spent over a decade with the same carrier, absorbing back-to-back 19% increases on a ~$1.1M plan, no claims data, no visibility, no idea where the money went. Bundled pharmacy that never got evaluated on its own. Standard story.
We didn’t start with a wellness program. We started with the contract.
Once we had the actual claims file, the pharmacy problem was obvious: three specialty drugs were running $35,000 a month through a PBM with no incentive to fix it. We repriced it, moved to an independent, pass-through PBM (SmithRx), and direct contracted the medical side.
The result:
- 85% pharmacy cost reduction — within 30 days
- 20% lower medical claims after direct contracting
- Total plan spend down 26% vs. benchmark
- Employee satisfaction at an all-time high
The line that tells you everything: “I have a prescription that used to cost $127 per fill with Cigna, it’s now $5.” – Jessi, HR Manager, True Fitness
Same drugs. Same members. Same utilization. The only thing that changed was who sat in the middle. Read the full True Fitness case study →
The mistakes I see most often
After running these analyses across a lot of mid-sized employers, the same four errors show up:
- Buying pharmacy as a bundled feature. The carrier’s PBM comes with the medical plan, so it never gets evaluated on its own merits. It should be underwritten separately, every time.
- Comparing discount guarantees instead of net cost. Discount and rebate guarantees are marketing. Net PMPM is math.
- Accepting the contract’s definitions. The savings live in the definitions section of “generic,” of “rebate,” of “specialty.” Change the definitions and you change the price without changing a single guarantee.
- Never repricing. A claims repricing takes 12 months of your actual utilization and runs it through an alternative PBM’s contract. It costs you nothing but the data pull. Most employers have simply never asked for one.
The test to run this week
Pull your last 12 months of pharmacy claims and reprice them against an independent, pass-through contract. That’s it. It’s the same drugs, the same members, the same utilization,t he only variable is who’s in the middle.
If the answer is that your current PBM is competitive, you’ve lost nothing and gained a defensible file for your next board meeting. If it isn’t, you’ve just found the cheapest savings available to you — no network disruption, no plan design change, nothing your employees will feel.
Pharmacy is where we start with most clients for exactly this reason. If you want to see how this fits with the rest of a cost-containment strategy, our pharmacy strategy approach lays out the sequence, and it pairs naturally with direct contracting on the medical side. Employers moving to self-funded health plans get the most leverage here, though even groups on level-funded plans have more room to move than they’re usually told.
Stop waiting for the market to fix itself
The three big PBMs are not going to voluntarily hand back margin. Congress may or may not act, and on a timeline that won’t help your 2027 renewal.
But you don’t need either of them. The alternative PBM market already exists, it already works, and the only thing standing between you and a real number is a data file you already own.
Ready to see what you actually paid versus what you could have paid? Find your fit with BeneSmart and we’ll run the analysis.